



November 2009  
EMEA/CHMP/ICH/730028/2009

**ICH Topic Q4B Annex 11  
Capillary Electrophoresis  
General Chapter**

**Step 3**

**ANNEX 11 TO NOTE FOR EVALUATION AND RECOMMENDATION OF  
PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS  
ON  
CAPILLARY ELECTROPHORESIS GENERAL CHAPTER  
(EMEA/CHMP/ICH/730028/2009)**

TRANSMISSION TO CHMP	November 2009
TRANSMISSION TO INTERESTED PARTIES	November 2009
DEADLINE FOR COMMENTS	February 2010

Please forward your comments to the following email address: [ich@emea.europa.eu](mailto:ich@emea.europa.eu)

## TABLE OF CONTENTS

<b>1. INTRODUCTION</b> .....	<b>3</b>
<b>2. Q4B OUTCOME</b> .....	<b>3</b>
2.1 ANALYTICAL PROCEDURES.....	3
2.2 ACCEPTANCE CRITERIA .....	3
<b>3. TIMING OF ANNEX IMPLEMENTATION</b> .....	<b>3</b>
<b>4. CONSIDERATIONS FOR IMPLEMENTATION</b> .....	<b>3</b>
4.1 GENERAL CONSIDERATION .....	3
4.2 FDA CONSIDERATION .....	3
4.3 EU CONSIDERATION .....	3
4.4 MHLW CONSIDERATION.....	4
<b>5. REFERENCES USED FOR THE Q4B EVALUATION</b> .....	<b>4</b>

## 1. INTRODUCTION

This annex is the result of the Q4B process for the Capillary Electrophoresis General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

## 2. Q4B OUTCOME

### 2.1 Analytical Procedures

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph.Eur. 2.2.47. Capillary Electrophoresis, JP General Information 4. Capillary Electrophoresis, and USP General Information Chapter <1053> Biotechnology-derived Articles – Capillary Electrophoresis,<sup>1</sup> can be used as interchangeable in the ICH regions.

### 2.2 Acceptance Criteria

The texts evaluated did not contain acceptance criteria.

## 3. TIMING OF ANNEX IMPLEMENTATION

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

## 4. CONSIDERATIONS FOR IMPLEMENTATION

### 4.1 General Consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

### 4.2 FDA Consideration

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

### 4.3 EU Consideration

For the European Union, regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the

---

<sup>1</sup> The harmonized text under review has been incorporated into USP informational chapter <1053> *Biotechnology-derived Articles – Capillary Electrophoresis*, which is official (as of the July 1, 2009, USP Revision Bulletin). The USP will propose in *Pharmacopoeial Forum* (Vol. 36, number 1) to drop the existing (mandatory) General Chapter <727> *Capillary Electrophoresis* (also now official), and rename the (nonmandatory) chapter <1053> to *Capillary Electrophoresis*. The proposed official date for this change will be May 1, 2011 (USP 34-NF29).

requirements for compliance with the Ph. Eur. Chapter 2.2.47. on the basis of the declaration of interchangeability made above.

#### **4.4 MHLW Consideration**

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

### **5. REFERENCES USED FOR THE Q4B EVALUATION**

**5.1** The PDG Stage 5B sign-off document: *Japanese Pharmacopoeial Forum*, Volume 11, number 4 (October 2002).

**5.2** The pharmacopoeial references for Capillary Electrophoresis General Chapter for this annex are:

*5.2.1 European Pharmacopoeia (Ph. Eur.):*

Supplement 6.6 (published June 2009, and official January 1, 2010), Capillary Electrophoresis (reference 01/2008:20247).

*5.2.2 Japanese Pharmacopoeia (JP):*

General Information 4. as it appears in the JP Fifteenth Edition (March 31, 2006, The Ministry of Health, Labour and Welfare Ministerial Notification No. 285). The English text was officially updated by errata published by MHLW at

[http://www.std.pmda.go.jp/jpPUB/Data/ENG/jpdata/H201105\\_jp15\\_errata.pdf](http://www.std.pmda.go.jp/jpPUB/Data/ENG/jpdata/H201105_jp15_errata.pdf) on November 5, 2008.

*5.2.3 United States Pharmacopeia (USP):*<sup>2</sup>

<1053> Biotechnology-derived Articles – Capillary Electrophoresis, USP *Revision Bulletin* posted May 29, 2009, official July 1, 2009.

---

<sup>2</sup> See footnote 1